Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
Department of Cardiothoracic Surgery, The Royal Prince Alfred Hospital, Sydney, Australia.
J Cardiovasc Surg (Torino). 2021 Jun;62(3):258-267. doi: 10.23736/S0021-9509.20.11443-5. Epub 2020 Sep 4.
Septal myectomy during open aortic valve replacement (AVR) is an effective surgical treatment for asymmetric secondary basal septal hypertrophy. Concerns regarding higher rates of complications associated with this procedure have been raised - such as permanent pacemaker implantation. The aim of this study was to compare outcomes and complications of patients with and without concomitant septal myectomy using propensity score matching applied to a large, consecutive single center cohort.
A total of 2199 consecutive patients undergoing either AVR with concomitant myectomy (AVR-M, N.=212) or AVR alone (N.=1987) were analyzed (2009-2015). Patients with previous cardiac or emergency surgery, concomitant cardiac procedures and endocarditis were excluded. As reference to previously published data, patient characteristics and outcomes of the overall cohort were examined and for comparison between groups propensity score matching utilized.
In the unmatched cohort, AVR-M patients were older (71.2±8 vs. 67.6±10 years, P<0.001) and more often female (68% vs. 37%, P<0.001) in comparison to patients receiving only AVR. After matching (N.=374) no significant difference in baseline features was evident. No significant difference in hospital mortality (2.1% vs. 1.6%, P=1.000) and pacemaker-implantation rate (5.3% vs. 3.7%, P=0.621) was observed. Mid-term survival was comparable between the two groups (86.1±5% vs. 84.4±5% after 6 years, P=0.957). The overall patient cohort showed a survival comparable to that of an adjusted regional normal population (P=0.178).
This study demonstrates that concomitant myectomy in patients undergoing AVR is a safe surgical technique resulting in comparable hospital mortality and mid-term survival. Concomitant septal myectomy seems not to be associated with an increased pacemaker implantation rate.
在开放式主动脉瓣置换术(AVR)期间进行间隔心肌切除术是治疗非对称基底间隔肥厚的有效手术治疗方法。有人担心这种手术的并发症发生率较高,例如需要植入永久性起搏器。本研究的目的是通过应用倾向评分匹配分析大型连续单中心队列,比较接受和不接受同期间隔心肌切除术的患者的结局和并发症。
共分析了 2199 例连续接受 AVR 联合心肌切除术(AVR-M,N.=212)或单纯 AVR(N.=1987)的患者(2009-2015 年)。排除既往心脏或急诊手术、同期心脏手术和心内膜炎的患者。作为对以前发表数据的参考,检查了整个队列的患者特征和结局,并进行了组间倾向评分匹配比较。
在未匹配的队列中,与仅接受 AVR 的患者相比,AVR-M 患者年龄较大(71.2±8 岁 vs. 67.6±10 岁,P<0.001)且更常为女性(68% vs. 37%,P<0.001)。匹配后(N.=374),基线特征无显著差异。两组间住院死亡率(2.1% vs. 1.6%,P=1.000)和起搏器植入率(5.3% vs. 3.7%,P=0.621)无显著差异。两组的中期生存率相当(6 年后分别为 86.1±5%和 84.4±5%,P=0.957)。整个患者队列的生存率与调整后的区域正常人群相当(P=0.178)。
本研究表明,AVR 患者同期行心肌切除术是一种安全的手术技术,可导致相似的住院死亡率和中期生存率。同期间隔心肌切除术似乎与起搏器植入率的增加无关。